User profiles for Kevin Brown
Kevin R BrownHospital for Sick Children Verified email at sickkids.ca Cited by 11657 |
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management
…, JJ Egan, FJ Martinez, J Behr, KK Brown… - American journal of …, 2011 - atsjournals.org
This document is an international evidence-based guideline on the diagnosis and management
of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic …
of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic …
[HTML][HTML] Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
…, G Raghu, A Azuma, KK Brown… - … England Journal of …, 2014 - Mass Medical Soc
Background Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that
targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of …
targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of …
Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline
Background: This document provides clinical recommendations for the diagnosis of
idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American …
idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American …
[HTML][HTML] Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant
…, M Edmunds, M Zambon, KE Brown… - … England Journal of …, 2021 - Mass Medical Soc
Background The B.1.617.2 (delta) variant of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …
An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial …
Background: In 2002 the American Thoracic Society/European Respiratory Society (ATS/ERS)
classification of idiopathic interstitial pneumonias (IIPs) defined seven specific entities, …
classification of idiopathic interstitial pneumonias (IIPs) defined seven specific entities, …
[HTML][HTML] Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant
…, M Edmunds, M Zambon, KE Brown… - The New England …, 2021 - ncbi.nlm.nih.gov
Background The B. 1.617. 2 (delta) variant of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …
[HTML][HTML] Nintedanib in progressive fibrosing interstitial lung diseases
…, R Schlenker-Herceg, KK Brown - … England Journal of …, 2019 - Mass Medical Soc
Background Preclinical data have suggested that nintedanib, an intracellular inhibitor of
tyrosine kinases, inhibits processes involved in the progression of lung fibrosis. Although the …
tyrosine kinases, inhibits processes involved in the progression of lung fibrosis. Although the …
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England …
…, S Cottrell, R Roberts, M O'Doherty, K Brown… - bmj, 2021 - bmj.com
Objective To estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and
Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the …
Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the …
[HTML][HTML] Duration of protection against mild and severe disease by Covid-19 vaccines
…, M Edmunds, M Zambon, K Brown… - … England Journal of …, 2022 - Mass Medical Soc
Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
Acute exacerbations of idiopathic pulmonary fibrosis
…, BB Moore, KR Flaherty, KK Brown… - American journal of …, 2007 - atsjournals.org
The natural history of idiopathic pulmonary fibrosis (IPF) has been characterized as a steady,
predictable decline in lung function over time. Recent evidence suggests that some …
predictable decline in lung function over time. Recent evidence suggests that some …